Research
105. Intranasal 5-MeO-DMT: Safety, PK and Effect on Altered States of Consciousness in Healthy Volunteers
Biological Psychiatry – April 10, 2023
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Benzydamine-An Affordable Over-the-Counter Drug with Psychoactive Properties-From Chemical Structure to Possible Pharmacological Properties.
Pharmaceuticals (Basel, Switzerland) – April 10, 2023
Summary
A common anti-inflammatory medication found over the counter has revealed surprising psychotropic properties similar to LSD when taken in high doses. Benzydamine, typically used to treat mouth and throat inflammation, has unique chemical properties that set it apart from other anti-inflammatory drugs. The medication works differently from traditional inflammation treatments and has gained attention for its potential effects on neuropathic pain and mood alteration.
Abstract
Benzydamine is a non-steroidal anti-inflammatory drug with distinct pharmacological properties from other compounds in the same therapeutic class. ...
The Effect of Daily Meditative Practices Based on Mindfulness and Self-Compassion on Emotional Distress under Stressful Conditions: A Randomized Controlled Trial.
European journal of investigation in health, psychology and education – April 10, 2023
Summary
No Summary
Abstract
Intervention programs based on self-compassion have demonstrated their efficacy both in reducing psychological distress and increasing well-being. ...
Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding.
Translational psychiatry – April 08, 2023
Summary
Psychedelic compounds affect men and women differently when processing fear and threats in the brain. Scientists found that psilocin, the active component in magic mushrooms, changes activity in a key emotional brain region called the amygdala in distinct ways between sexes. While females showed increased reactivity to threatening stimuli immediately after treatment, males experienced reduced fear responses that lasted up to 28 days. These findings help explain why psychedelics may work differently across genders in treating anxiety and mood disorders.
Abstract
Psilocybin and its active metabolite psilocin have been shown to elicit rapid and long-lasting symptom improvements in a variety of affective psych...
Isha yoga practices, vegan diet, and participation in Samyama meditation retreat: impact on the gut microbiome & metabolome - a non-randomized trial.
BMC complementary medicine and therapies – April 05, 2023
Summary
No Summary
Abstract
Growing evidence suggests a role for gut bacteria and their metabolites in host-signaling responses along the gut-brain axis which may impact menta...
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique
Frontiers in Psychiatry – April 05, 2023
Summary
A critical insight reveals *Psychedelics and Drug Studies* often misinterpret "mystical experiences" from compounds influencing *Neurotransmitter Receptor Influence on Behavior*. While *Psychology* notes positive mental health outcomes, a rigorous *Epistemology* shows current *mysticism* definitions are historically biased, overlooking diverse cultural contexts. This impacts how *Psychotherapists* apply insights. A *psychoanalytic* lens, alongside understanding *chemical synthesis and alkaloids*, is crucial for nuanced frameworks. Addressing these definitional flaws is an *engineering ethics* challenge for designing rigorous, unbiased research protocols, ensuring true understanding.
Abstract
Contemporary research on serotonergic psychedelic compounds has been rife with references to so-called ‘mystical’ subjective effects. Several psych...
Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants
Archives of Razi Institute – April 04, 2023
Summary
A promising avenue for treating major depression involves 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), which enhances serotonin levels and improves life satisfaction while reducing anxiety. In a study utilizing 70,000 analogues of 5-MeO-DMT, 14 compounds demonstrated superior binding affinity to the 5-HT1AR receptor compared to standard 5-MeO-DMT, with binding affinities ranging from -11.41 to -6.53 kcal/mol versus -7.75 kcal/mol for 5-MeO-DMT. Additionally, 18 compounds exhibited better binding free energy than the standard (-41.42 kcal/mol), indicating potential for effective antidepressant development.
Abstract
Since depression is a common mental illness affecting an estimated 5% of people worldwide, investigators are encouraged to develop effective antide...
Liquid light. Ayahuasca spirituality and the Santo Daime tradition
Politics Religion & Ideology – April 03, 2023
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Frontiers in Psychology – April 03, 2023
Summary
Psychedelics profoundly alter lived experience, sparking new **cognitive psychology** into their mechanisms. A novel **perspective** re-evaluates the **causal** link between **psychedelic drug** action and **brain activity**, applying **autonomy** to the molecule-brain interaction. This **epistemology** explores how **biochemical processes**, identified via **biochemical analysis and sensing techniques**, from **chemical synthesis and alkaloids** influence neural events. It then connects these to experience using **neurophenomenology**. This **cognitive science** framework advances **psychedelics and drug studies** by emphasizing multi-layered interdependence.
Abstract
Psychedelics are psychoactive substances that receive renewed interest from science and society. Increasing empirical evidence shows that the effec...
Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs
Neuropharmacology – April 02, 2023
Summary
For many suffering chronic pain, existing medicine and psychosocial treatments are ineffective or cause distress. Excitingly, preliminary evidence suggests psychedelics could significantly improve quality of life and tolerability, aligning with a biopsychosocial model focused on acceptance rather than complete pain elimination. Clinical psychology and psychiatry are exploring if these effects, relevant to alternative medicine and drug studies involving chemical synthesis and alkaloids, are direct or mediated by psychological shifts. Developing new psychotherapeutic strategies based on this understanding is a crucial next step.
Abstract
Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the Unite...
Clinical pharmacological innovation in the treatment of depression.
Expert review of clinical pharmacology – April 01, 2023
Summary
No Summary
Abstract
Deficiencies in standard of care antidepressants are driving novel drug discovery. A new age of antidepressant medications has emerged with the int...
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
Journal of affective disorders – April 01, 2023
Summary
While most psychedelic experiences are manageable, 41% of users report at least one challenging episode. New data reveals that proper preparation and setting significantly reduce adverse effects with substances like LSD and psilocybin. Mental state, environment, and support are key factors affecting risk. Only 2.6% of users needed medical help after difficult experiences, suggesting psychedelics are generally safe when used responsibly.
Abstract
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence...
The Varieties of Psychedelic Expertise in 1960s Canada: The Psychiatrists behind the Addiction Research Foundation's Study of LSD Therapy.
Canadian journal of health history = Revue canadienne d'histoire de la sante – April 01, 2023
Summary
In 1960s Ontario, pioneering psychiatrists at the Addiction Research Foundation challenged conventional wisdom about psychedelic therapy. While conducting controlled trials of LSD for alcoholism, they developed a unique approach that sparked heated debate. Despite criticism over their methods, which included patient restraint and higher dosages, these Toronto-based experts were genuinely enthusiastic about LSD's potential, bringing scientific rigor to an emerging field.
Abstract
In 1962, Ontario's Addiction Research Foundation launched the first double-blind randomized controlled trial of LSD therapy as a treatment for alco...
IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.
Pharmacological research – April 01, 2023
Summary
A single dose of this unique hallucinogen has been reported to alleviate drug craving and prevent relapse for months. This powerful psychedelic is being explored as an addiction drug therapy, especially for opioid use disorder. It rapidly metabolizes into noribogaine via enzymes like cyp2d6. Its effectiveness stems from polypharmacology, interacting with multiple brain targets simultaneously. Showing positive results in pilot studies and animal models, ongoing clinical trials are carefully monitoring potential cardiac effects, such as on the qt interval, as it progresses through development.
Abstract
Ibogaine is a powerful psychoactive substance that not only alters perception, mood and affect, but also stops addictive behaviors. Ibogaine has a ...
Classic psychedelic use and current meditation practice.
Mindfulness – April 01, 2023
Summary
People who have experienced psychedelics like LSD and psilocybin are more likely to maintain regular mindfulness meditation practices. A large U.S. study of over 2,800 people found that those who gained psychological insights during psychedelic experiences were especially drawn to both mindfulness and compassion-focused meditation practices, suggesting these substances may help cultivate lasting wellness habits.
Abstract
Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known ab...
New trends of new psychoactive substances (NPS)-infused chocolate: Identification and quantification of trace level of NPS in complex matrix by GC-MS and NMR.
Talanta – April 01, 2023
Summary
For the first time, illicit new psychoactive substances (NPS) have been identified and quantified in chocolate. Analysis of 65 seized chocolate samples revealed 11 different NPS types, with concentrations ranging from 0.5 mg/g to 44.1 mg/g. A robust (1)H qNMR and (19)F qNMR method was developed for the identification and quantification of 297 NPS, distinguishing aromatic isomer variants. This crucial development, with recoveries of 91.7%–104.4% and reproducibility below 3.6%, helps combat serious health risks from contaminated chocolate.
Abstract
For the first time, the identification and quantification of trace level of new psychoactive substances (NPS) in a complex chocolate matrix have be...
Use of Selective Alternative Therapies for Treatment of OCD
Neuropsychiatric Disease and Treatment – April 01, 2023
Summary
A compelling 40% of individuals with Obsessive-Compulsive Spectrum Disorders don't respond to existing medicine. A systematic review of 16 observational studies, from sources like Cochrane Library and MEDLINE, explored alternative drug options. Examining Psilocybin (4 studies), Cannabis (7 studies), Nicotine (3 studies), and Morphine (2 studies), positive effects were reported by all Psilocybin and morphine users, 88.2% of nicotine users, and 74.1% of Cannabis users. Tolerability was generally good, though some experienced worsening symptoms. This offers promising avenues for Psychiatry, Internal medicine, and Psychedelics and Drug Studies.
Abstract
About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several ...
Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice.
Cureus – April 01, 2023
Summary
Medical students who know more about magic mushrooms are more likely to support their therapeutic use. A survey of 213 future doctors revealed that those with greater knowledge of psilocybin and support for its legalization had more positive views about using it in mental health and palliative care. Despite psilocybin's current status as a schedule 1 drug, medical education may need to evolve as alternative medicine gains acceptance.
Abstract
Background Psilocybin use, along with other psychedelics, has seen an increased interest among professionals in the medical community due to its po...
Examining the Therapeutic Effect of Ceremonial Ayahuasca on Narcissistic Personality and Antagonistic Externalizing in Adults.
Journal of personality disorders – April 01, 2023
Summary
Traditional ayahuasca ceremonies show promise in reducing negative narcissistic traits like entitlement and exploitation. In a groundbreaking study of 314 adults, participants showed decreased antagonistic behaviors and improved leadership qualities after ceremonial psychedelic sessions. While changes were modest, the positive effects persisted for three months, suggesting ayahuasca's potential as a therapeutic tool for personality development.
Abstract
Changes in narcissistic traits (e.g., entitlement) following the ceremonial use of ayahuasca were examined across three timepoints (baseline, postr...
Systematic Review of Interventions for Demoralization in Patients With Cancer.
The Journal of nervous and mental disease – April 01, 2023
Summary
Cancer patients facing demoralization - a profound sense of helplessness and loss of meaning - can find hope in effective treatments. Both psychedelic-assisted therapy and traditional psychological interventions show promising results in restoring patients' sense of purpose and resilience. Analysis of 14 clinical studies reveals that most approaches successfully reduced demoralization, with 10 programs demonstrating clear positive outcomes.
Abstract
Demoralization as cancer-related mental health needs to be understood and addressed by clinical staff. This review systematically examined the char...
Meditation Practice, Mindfulness, and Pain-Related Outcomes in Mindfulness-Based Treatment for Episodic Migraine.
Mindfulness – April 01, 2023
Summary
No Summary
Abstract
Mindfulness-based interventions (MBIs) have emerged as promising prophylactic episodic migraine treatments. The present study investigated biopsych...
The high frequency oscillation in orbitofrontal cortex is susceptible to phenethylamine psychedelic 25C-NBOMe in male rats.
Neuropharmacology – April 01, 2023
Summary
Psychedelics like 25C-NBOMe profoundly alter brain activity. A 0.1 mg/kg dose of 25C-NBOMe in rats boosted High frequency oscillation (120-150 Hz) specifically in the orbitofrontal Prefrontal cortex, peaking in 20-30 minutes. This increased activity strengthened Oscillatory coherence *within* prefrontal regions. These findings illuminate how psychedelics reorganize brain rhythms, potentially explaining their mind-altering effects and offering a biological marker for their impact.
Abstract
Serotoninergic psychedelics induced extensive alterations in perception and cognition, which has been attributable to its disruptive effect on osci...
Prenatal ketamine exposure impairs prepulse inhibition via arginine vasopressin receptor 1A-mediated GABAergic neuronal dysfunction in the striatum.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie – April 01, 2023
Summary
Prenatal exposure to N-methyl-D-aspartate receptor antagonists like ketamine or Methoxetamine can induce psychosis-like behaviors in offspring. Administering these to pregnant rats led to reduced Prepulse inhibition and increased Arginine vasopressin receptor 1A expression in offspring's striatum. Overexpressing Arginine vasopressin receptor 1A inhibited Prepulse inhibition. Treatment also elevated δ-aminobutyric acid levels. This indicates prenatal N-methyl-D-aspartate receptor antagonist exposure causes δ-aminobutyric acid neuronal dysfunction and sensorimotor gating issues by regulating Arginine vasopressin receptor 1A.
Abstract
Ketamine is a widely used anesthetic with N-methyl-D-aspartate (NMDA) receptor antagonism. Exposure to ketamine and NMDA receptor antagonists may i...
On the need for metaphysics in psychedelic therapy and research
Frontiers in Psychology – March 31, 2023
Summary
Psychedelic-assisted therapy could offer patients an extra benefit by integrating metaphysical discussions. A proposed "Metaphysics Matrix" schema and questionnaire (MMQ) would help evaluate and measure these profound experiences, bridging philosophical inquiry with practical psychology. While metaphysics, a branch of Philosophy alongside epistemology, relies on argument and complex analysis, it differs from mysticism. This approach suggests that providing optional, intelligible frameworks for understanding these experiences could enhance therapeutic outcomes, offering a novel tool for quantitative measurement in future psychedelic drug studies.
Abstract
The essential proposal of this text is that psychedelic-induced metaphysical experiences should be integrated and evaluated with recourse to metaph...
Psychotherapy with Psilocybin for Depression: Systematic Review
Behavioral Sciences – March 31, 2023
Summary
Psilocybin offers a powerful new approach in medicine for mental health, rapidly improving depressive symptoms for months. Eight clinical psychology studies highlight its potential, even for treatment-resistant depression affecting 280 million people globally, a significant economic burden. Administered with psychotherapist support, this psychedelic, a naturally occurring alkaloid, fosters deep introspection and well-being after just one or two doses, influencing behavior through neurotransmitter pathways. This represents a significant development in psychiatry and drug studies.
Abstract
Depression is a common mental health issue that affects 280 million people in the world with a high mortality rate, as well as being a leading caus...
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity
Chinese Medical Journal – March 30, 2023
Summary
A single dose of psilocybin (2.5 mg/kg) rapidly and durably reduced fear responses in mice for up to seven days. This neuroscience finding suggests psychedelics could revolutionize cognitive psychology and psychotherapist approaches to PTSD. Psilocybin facilitates fear extinction by promoting neuroplasticity within the hippocampal formation. This alkaloid, studied in chemical synthesis and drug studies, influences neurotransmitter receptors, rescuing reductions in hippocampal dendritic complexity and neurogenesis. This powerful effect on brain structure offers a promising avenue for medicine.
Abstract
Abstract Background: Posttraumatic stress disorder (PTSD) and depression are highly comorbid. Psilocybin exerts substantial therapeutic effects on ...
Systematic Review of Interventions for Demoralization in Patients With Cancer
The Journal of Nervous and Mental Disease – March 28, 2023
Summary
Effective interventions exist for cancer patients experiencing demoralization. A systematic review, drawing from databases like PsycINFO, CINAHL, MEDLINE, and Cochrane Library, analyzed 14 studies. Ten of these (over 70%) showed positive effects, highlighting successful psychological intervention and psilocybin-assisted psychotherapy. This meta-analysis in clinical psychology underscores how psychotherapists can improve mental health and psychiatry outcomes. Such intervention (counseling) strategies are vital in medicine, encompassing Psychedelics and Drug Studies and various Psychotherapy Techniques and Applications.
Abstract
Abstract Demoralization as cancer-related mental health needs to be understood and addressed by clinical staff. This review systematically examined...
Contribution of serotonin 5-HT<sub>2A</sub> receptor to antidepressant effect of serotonergic psychedelics
Folia Pharmacologica Japonica – March 28, 2023
Summary
A compelling finding in Medicine reveals that 30-40% of major depressive disorder patients are treatment-resistant. While Ketamine offers an antidepressant option, Psilocybin, a Serotonergic hallucinogen alkaloid, is emerging as a safer alternative. Recognized by the FDA as a "breakthrough therapy," Psilocybin shows fast, lasting effects, even for treatment-resistant cases. This "psychedelic renaissance" in Psychiatry explores how these compounds, including Lysergic acid diethylamide, influence Serotonin receptors. Psychology and Pharmacology are delving into their mechanisms, offering hope for Anxiety and depression via Neurotransmitter Receptor Influence on Behavior, advancing Psychedelics and Drug Studies.
Abstract
Major depressive disorder presents a substantial global health burden, and at least 30-40% of patients exhibit treatment resistance to antidepressa...
Human brain effects of DMT assessed via EEG-fMRI.
Proceedings of the National Academy of Sciences of the United States of America – March 28, 2023
Summary
Dimethyltryptamine (DMT), a powerful psychedelic found naturally in ayahuasca, dramatically alters consciousness by acting on serotonin receptors in the brain. Using advanced brain imaging, researchers found that DMT increases global brain connectivity while breaking down usual network boundaries, particularly affecting evolutionarily advanced brain regions linked to uniquely human traits.
Abstract
Psychedelics have attracted medical interest, but their effects on human brain function are incompletely understood. In a comprehensive, within-sub...
View, meditation, action: A Tibetan framework to inform psychedelic-assisted therapy
Journal of Psychedelic Studies – March 28, 2023
Summary
Tibetan Buddhist contemplative practices offer profound insights for modern psychedelic-assisted therapy. Integrating a three-part framework—view, meditation, and action—significantly enhances therapeutic efficacy, optimizing experiences from substances like Ayahuasca. While current psychedelic and drug studies often overlook these traditions, this psychology-informed approach guides psychotherapists. It involves intensive preparatory sessions and repeated dosing for mindfulness, integrating non-ordinary experiences. Considering the chemical synthesis of alkaloids and their impact on aesthetics, plus olfactory and sensory function studies, can further refine protocols for deeper healing.
Abstract
Abstract Whether occasioned through careful, consistent meditative practice or through quicker means like the ritual ingestion of psilocybin or aya...
'More evolved than you': Evolutionary spirituality as a cultural frame for psychedelic experiences.
Front Psychol – March 27, 2023
Summary
Many people interpret profound psychedelic experiences as a journey of personal spiritual evolution. Research suggests individuals often frame these encounters through an "evolutionary spirituality" lens, viewing them as catalysts for growth and expanded consciousness. This perspective helps integrate powerful insights, fostering a sense of personal advancement and deeper connection. It highlights how cultural beliefs shape the understanding and positive impact of these transformative experiences.
Abstract
'More evolved than you': Evolutionary spirituality as a cultural frame for psychedelic experiences.
Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism
Cells – March 22, 2023
Summary
Psychedelics show encouraging results for treating alcohol addiction, a major public health issue. This Neuroscience review synthesizes how psychedelics, via serotonin 2A receptors, restore function of the metabotropic glutamate receptor 2 (mGlu2). Understanding this metabotropic receptor crosstalk, including related glutamate receptors like metabotropic glutamate receptor 5, offers crucial insight into Neurotransmitter Receptor Influence on Behavior. This pharmacology insight, informed by Bioinformatics and Biochemical Analysis, paves the way for new medicine.
Abstract
Alcohol abuse is a leading risk factor for the public health burden worldwide. Approved pharmacotherapies have demonstrated limited effectiveness o...
Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects
American Journal of Psychiatry – March 22, 2023
Summary
No Summary
Abstract
Abstract not available from OpenAlex
The Unique Neural Signature of Your Trip: Functional Connectome Fingerprints of Subjective Psilocybin Experience
OpenAlex – March 21, 2023
Summary
Psilocybin, a powerful hallucinogen, creates highly unique "brain fingerprints" that predict subjective psychedelic experiences. Using functional neuroimaging (fMRI), individual functional connectomes became more idiosyncratic post-psilocybin, concentrating in the Default Mode Network (DMN). This DMN connectome pattern, showing reduced internal and limbic connectivity but increased links to attentional systems, was central. This neuroscience and psychology work, leveraging brain fingerprinting, advances psychedelics and drug studies, bridging brain changes with behavior and highlighting psilocybin's (an alkaloid) neurotransmitter receptor influence.
Abstract
Abstract The emerging neuroscientific frontier of brain fingerprinting has recently established that human functional connectomes (FCs) exhibit fin...
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Journal of Psychopharmacology – March 20, 2023
Summary
Psilocybin, a hallucinogen, demonstrated significant antidepressant effects for major depressive disorder. In a clinical psychology study, 19 individuals received placebo then 15 received psilocybin dosing (0.3 mg/kg); response rates reached 66.7% and remission 46.7%. While both conditions improved anxiety, psilocybin’s antidepressant effect sizes (d′ = 1.02–2.27) surpassed placebo’s (d′ = 0.65–0.99). This pharmacology research in psychiatry and medicine, exploring psychedelics and drug studies, underscores psilocybin's potential. Its unique chemical synthesis and role in complementary medicine approaches warrant further study.
Abstract
Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects f...
Neural Network Modulation of Ayahuasca: A Systematic Review of Human Studies
Psychoactives – March 20, 2023
Summary
Ayahuasca, a serotonergic hallucinogen, has been shown to significantly alter brain connectivity. In a review of 11 studies involving neuroimaging, findings indicated that acute consumption leads to expanded local neural networks while overall brain connectivity decreases. Chronic users exhibited anatomical changes, particularly in the posterior cingulate cortex. Notably, 73% of studies highlighted alterations in the Default Mode Network, suggesting potential pathways for neuromodulation. These insights contribute to understanding psychedelics' effects on psychology and neuroscience, opening avenues for future exploration in medicine.
Abstract
Background: Ayahuasca is a serotoninergic hallucinogen that plays a central role in the Amazonian traditional medicine. Its psychoactive effects ar...
Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review
Journal of Psychoactive Drugs – March 18, 2023
Summary
Promising insights emerge for psychedelic medicine in psychiatry. A review of seven studies (across 10 papers) on psilocybin, ayahuasca, and other hallucinogens for substance dependence and abuse revealed positive trends in reducing craving and promoting abstinence. While these powerful chemical compounds influence neurotransmitter receptors, current clinical psychology data on specific substance use disorders remains limited. Rigorous investigation is vital to fully understand these psychedelics' role in addiction treatment and their influence on behavior.
Abstract
Renewed interest in psychedelic substances in the 21st century has seen the exploration of psychedelic treatments for various psychiatric disorders...
Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD
OpenAlex – March 17, 2023
Summary
A new randomized controlled trial explores the therapeutic potential of psilocybin, a potent hallucinogen and alkaloid, for obsessive-compulsive disorder. Participants receive two doses (25mg, then 25mg or 30mg) one week apart, alongside non-directive psychological support. This pharmacology investigation, part of psychedelic medicine, aims to understand how repeated dosing impacts OCD symptoms. Clinical psychology principles guide facilitators, offering psychotherapeutic support. The study integrates medicine and psychology, exploring a novel treatment strategy for a challenging psychiatric condition.
Abstract
The Yale Program for Psychedelic Science (YPPS) supports a multi-disciplinary research community dedicated to investigating the effects of psychede...
Mush Room for Improving Therapeutic Approaches in Psychiatry
Clinical Pharmacology & Therapeutics – March 15, 2023
Summary
Psilocybin, once a taboo "magic mushroom," is now a serious focus in medicine, moving beyond fictional drama's outrage. A recent extensive phase II clinical trial for treatment-resistant major depressive disorder yielded "intriguing and sobering" results, prompting a phase III study. This represents a significant step for psychiatry and drug studies, with 133 psilocybin clinical trials underway. Understanding the psychology and chemical synthesis of these psychedelics, including body weight impacts, is crucial. Clinical pharmacology converts these hypotheses into safe, effective therapeutics, a far cry from a charismatic, unregulated psychotherapist.
Abstract
In the televised fictional drama "Nine Perfect Strangers," based on a novel with the same name,1 nine people gather for a retreat in a wellness res...
Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
BMC psychiatry – March 14, 2023
Summary
Small doses of psychedelics like LSD and psilocybin may offer mental health benefits, according to users who carefully track their experiences. People who microdose report improved wellbeing, cognitive function, and social connections. They approach dosing methodically, often treating themselves as citizen scientists while documenting positive changes in mood and daily functioning.
Abstract
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that p...
The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice
Molecules – March 14, 2023
Summary
Psilocybin, a key compound in Psychedelics and Drug Studies, powerfully combats brain inflammation, revealing new avenues in Medicine. Pharmacology reveals that after Lipopolysaccharide-induced neuroinflammation via intraperitoneal injection in C57BL/6J mice, psilocybin alone or combined with eugenol, a natural anti-inflammatory, effectively reduced inflammatory markers. A 1:50 psilocybin-eugenol ratio proved most effective, dramatically decreasing cytokines like Tumor necrosis factor alpha and IL-6. Western blot confirmed reductions. This chemistry suggests novel treatments for Tryptophan and brain disorders linked to Neuroinflammation and Neurodegeneration Mechanisms.
Abstract
Inflammation is an organism’s biological defense mechanism. Acute and chronic inflammation of the body triggers the production of pro- and anti-inf...
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Frontiers in Psychiatry – March 14, 2023
Summary
Current psychological interventions for methamphetamine use disorder yield modest success, leaving a critical gap in Psychiatry and Medicine. Yet, the potent hallucinogen psilocybin, an alkaloid with known Neurotransmitter Receptor Influence on Behavior, presents a promising avenue. While no Clinical psychology studies exist for this specific application, Psychedelics and Drug Studies are investigating psilocybin-assisted psychotherapy. This innovative psychological intervention, combining a psychotherapist with psilocybin (a compound from chemical synthesis), offers new hope in Psychology to revolutionize treatment where current medicine falls short.
Abstract
Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates o...
Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders
Neuropharmacology – March 13, 2023
Summary
Psilocybin, a potent hallucinogen, offers remarkable promise in Psychiatry. Clinical trials reveal it rapidly improves treatment-resistant depression, with benefits lasting 3-12 months. This breakthrough in Medicine highlights the profound impact of Psychedelics and Drug Studies. Neuroscience explores how this chemical compound influences neurotransmitter receptors, altering behavior and improving synaptic function. Understanding these mechanisms is crucial for psychotherapists to integrate such alkaloid-based psychology treatments, advancing novel therapeutic approaches.
Abstract
Psychedelic compounds have shown extraordinary potential in treating a wide range of neuropsychiatric disorders. Psilocybin, for example, has now b...
Past, Present, and Future of Psychedelics: A <i>Psychedelic Medicine</i> Roundtable Discussion.
Psychedelic Med (New Rochelle) – March 13, 2023
Summary
Psychedelics are experiencing a remarkable renaissance in medicine. A gathering of leading experts explored their complex history, current scientific advancements, and future promise. The discussion highlighted compelling evidence of their therapeutic efficacy for mental health, underscoring successful clinical applications. This collective insight signals a bright future for integrating these powerful compounds into healthcare, offering transformative healing.
Abstract
Past, Present, and Future of Psychedelics: A Psychedelic Medicine Roundtable Discussion.
Proposed Consensus Statement on Defining Psychedelic Drugs.
Psychedelic Med (New Rochelle) – March 13, 2023
Summary
Establishing a clear, shared definition for psychedelic drugs is crucial for advancing research. Experts reviewed current understanding and proposed a consensus definition, emphasizing their unique pharmacological action and profound impact on perception. This precise framework promises to unify scientific discourse, fostering clearer communication and accelerating the development of these promising compounds for therapeutic benefit.
Abstract
Proposed Consensus Statement on Defining Psychedelic Drugs.
Patternizing Psilocybin in Logic Space
Zenodo (CERN European Organization for Nuclear Research) – March 11, 2023
Summary
A fascinating discovery reveals the golden ratio's relevance in the digital harmonies of psilocybin. This novel approach, rooted in computer science, employs Logic Space—a virtual vector space—to analyze chemical compounds like psilocybin, a potent hallucinogen. Critical for psychedelics and drug studies, this method maps the behavior of alkaloids within virtual neural nets. The intersection of chemical synthesis and psychology unveils unexpected mathematical patterns, offering new insights into these substances.
Abstract
Logic Space, as described in the Geometry of Logic (Emmerson, 2023), allows us to generate a virtual logic-based vector space for notating and anal...
Ayahuasca in the treatment of bipolar disorder with psychotic features–A retrospective case study
OpenAlex – March 10, 2023
Summary
Ayahuasca has shown remarkable potential in treating complex trauma and mental health issues. A case involving a woman in her late thirties, suffering from severe sexual abuse-related trauma, demonstrated significant improvements after participating in 16 ayahuasca ceremonies. Initially diagnosed with bipolar disorder and borderline personality disorder, she experienced a complete resolution of suicidality and reduced dissociative symptoms. Notably, she acknowledged her diagnosis as stemming from her trauma. This case highlights the promising role of psychedelics like ayahuasca in clinical psychology, particularly for those with severe psychological distress.
Abstract
Ayahuasca is a plant-based brew of indigenous Amazonian origin. It has psychedelic, anti-inflammatory, neuroprotective, cytotoxic, and anti-parasit...
Understanding psychedelic 'mystical experience'—A case example
OpenAlex – March 10, 2023
Summary
Psilocybin therapy can dramatically heal deep-seated family trauma. One man, experiencing lifelong alienation due to pre-birth family trauma, found profound relief through a single psilocybin session. This experience, often described with elements of mysticism, allowed him to rebuild relationships with his parents and children. Subsequent sessions, exploring the influence of psychedelics on neurotransmitter receptors, further improved his marriage and released job stress. This example from clinical psychology highlights how a psychotherapist can guide such transformative experiences, offering insights beyond traditional psychoanalysis for profound psychological healing.
Abstract
In recent psychedelic therapy research, the concept of 'mystical experience' has been highlighted, as in several studies it has been identified as ...
Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD—A retrospective case study
OpenAlex – March 10, 2023
Summary
A compelling case suggests psilocybin, a chemical synthesis alkaloid, could help individuals with severe anxiety and depression understand ordinary states like hopefulness. One individual, suffering early trauma and chronic anxiety and depression since childhood, found traditional psychotherapy and psychiatry unhelpful. Through intensive, self-directed psilocybin use from age 19, he reported achieving a foundational feeling of peace by age 30, despite ongoing societal trauma. This clinical psychology insight suggests psychedelics and drug studies may offer new avenues for treating treatment-resistant depression, influencing neurotransmitter receptor behavior.
Abstract
In medicine, psychedelics were initially considered as a tool for clinicians to understand psychotic states. Based on the presented case data, a re...
Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
ACS Pharmacology & Translational Science – March 10, 2023
Summary
Beyond the expected 5-HT2A receptor, new tryptamine psychedelics influence behavior through complex pharmacology, targeting multiple serotonin receptors, including 5-HT1A. Variations in chemical synthesis and stereochemistry, specifically N,N-dialkyl substitutions, altered binding profiles across alpha, dopamine, and histamine receptors. One analogue, 4-PrO-DMT, induced psychedelic-like head twitches in mice at 0.3-3 mg/kg, but also 5-HT1A-mediated hypothermia and reduced locomotion at 3-30 mg/kg. This suggests 5-HT1A activity can attenuate 5-HT2A-mediated effects, crucial for understanding neurotransmitter receptor influence on behavior in drug studies.
Abstract
Analogues of 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) are being sold on recreational drug markets and developed as potential medications...
Bioproduction platform using a novel cane toad (Rhinella marina) N-methyltransferase for psychedelic-inspired drug discovery
OpenAlex – March 10, 2023
Summary
A fascinating discovery in **biology** reveals an enzyme from the **cane toad** (*Rhinella marina*) that could revolutionize **bioproduction** for **drug discovery**. This indolethylamine N-methyltransferase (RmNMT), identified through **biochemical analysis**, is exceptionally efficient and versatile. Unlike similar enzymes, it facilitates the **chemical synthesis** of novel **psychedelics** and **alkaloids**. **Pharmacology** studies indicate that while N,N-dimethylated forms show reduced receptor engagement, only these compounds induce hallucinogenic behavior in mice, underscoring metabolic stability crucial for **Drug Studies**. This platform offers new avenues for therapeutic development.
Abstract
Abstract Psychedelic indolethylamines have emerged as potential medicines to treat several psychiatric pathologies. Natural sources of these compou...
History repeating: A roadmap to address common problems in psychedelic science
OpenAlex – March 10, 2023
Summary
Despite considerable optimism and political shifts regarding psychedelics for mental disorders in psychology, 10 pressing challenges severely limit conclusions about their safety and efficacy in drug studies. These issues compromise external validity and construct validity, impacting the quality and generalizability of findings. A new checklist, rooted in Generalizability theory, aims to address these problems, ensuring future research provides robust data and prevents history repeating itself, truly assessing if this widespread optimism is warranted.
Abstract
Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders....
Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin—A retrospective case study
OpenAlex – March 10, 2023
Summary
A woman with 30 years of treatment-resistant depression found lasting relief through psilocybin. After prior medications caused adverse effects and discontinuation, she engaged in six psilocybin sessions over 1.5 years. This approach in clinical psychology helped interrupt dissociative trauma responses. A 2.5-year follow-up confirmed remission, suggesting a multi-dose strategy with psychedelics can offer profound psychological healing. This case highlights how psilocybin, an alkaloid influencing neurotransmitter receptors, may resolve severe depression where traditional psychiatry failed, particularly for those experiencing early life trauma and feelings of abandonment.
Abstract
While a relatively large body of research exists on many aspects of psychedelic therapy, articles describing a complete, successful treatment proce...
The Near-Death Experience and Suicidal Ideation.
Omega – March 10, 2023
Summary
No Summary
Abstract
The near-death experience (NDE) most generally refers to a state of altered consciousness with various features that can occur during real or presu...
Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles.
Biomedicines – March 07, 2023
Summary
Brain inflammation may be a hidden driver of depression, with immune cells called microglia playing a key role. Scientists found that diverse antidepressants, from ketamine to cannabinoid compounds, work by controlling an enzyme called GSK3β in these brain immune cells. This discovery reveals how stress triggers depression and points to a new way to test potential treatments by measuring their effects on brain inflammation pathways.
Abstract
Depression is a major public health concern. Unfortunately, the present antidepressants often are insufficiently effective, whilst the discovery of...
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
Journal of Psychopharmacology – March 06, 2023
Summary
Many people self-treating mental health conditions with psychedelics report significant improvements. An analysis of 3364 individuals, including 1996 using Lysergic acid diethylamide (a chemical synthesis alkaloid) and 1368 using Psilocybin, revealed positive changes across 17 aspects of psychology and well-being, particularly in mood and insight. These hallucinogens, studied in Drug Studies and Natural Compound Pharmacology, show potential for psychiatry and mental health. However, 22.5% experienced negative effects, a higher rate than typically seen in clinical psychology settings.
Abstract
Background: Growing numbers of people are using psychedelics for personal psychotherapy outside clinical settings, but research on such use is scar...
TOLERANCE AND ACCEPTABILITY OF INTRAVENOUS KETAMINE THERAPY FOR TREATMENT RESISTANT DEPRESSION: A MIXED METHODS ASSESSMENT
Journal of Pakistan Psychiatric Society – March 03, 2023
Summary
Rapid, transformative relief from severe depression was observed in patients receiving IV ketamine. Among 14 individuals with treatment-resistant depression, significant improvements in symptom severity occurred at one hour and two weeks following the final dose of 6 infusions over two weeks. While these effects were not sustained at one month, most patients, initially hesitant, became advocates for ketamine therapy. This demonstrates ketamine's quick, acceptable impact on severe depressive symptoms, though longer-term benefits remain unestablished.
Abstract
Objectives: This study was conducted to evaluate the response of treatment resistant depression to IV ketamine therapy protocol and explore the per...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?
Cambridge Quarterly of Healthcare Ethics – March 02, 2023
Summary
Psychedelics like Psilocybin and MDMA show significant therapeutic potential for conditions from addiction to existential distress, marking a potential step change in Psychiatry. While their value stems from unique experiential learning, questions arise regarding psychotherapist training. Should future psychotherapists undergo hallucinogen experiences themselves? Current thinking suggests requiring such firsthand engagement isn't ethically legitimate without stronger evidence of its unique contribution to understanding psychology. However, permitting voluntary participation in Psychedelics and Drug Studies might be acceptable, acknowledging the diverse academic research themes involved.
Abstract
Abstract Recent research offers good reason to think that various psychedelic drugs—including psilocybin, ayahuasca, ketamine, MDMA, and LSD—may ha...
Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review
Antioxidants – March 02, 2023
Summary
Mushroom consumption significantly lowers the odds of depression. With major depression affecting over 322 million people worldwide and ~30% resistant to current antidepressant medicine, new pharmacological strategies are crucial. Insights from Fungal Biology and Applications reveal medicinal mushrooms contain bioactive compounds. These natural compounds, often explored in traditional medicine, offer promising pharmacological effects. They act as serotonin precursors or rapid-acting antidepressants, influencing neuroinflammation, neurogenesis, and the gut-brain axis, presenting novel avenues for medicine.
Abstract
Major Depression Disease is a common mental illness that affects more than 322 million people worldwide and it is one of the leading causes of ment...
Ayahuasca in Western society and the metacognitive counselling approach
Counselling and Psychotherapy Research – March 02, 2023
Summary
Ayahuasca, a powerful hallucinogenic plant used in South American healing rituals, risks misapplication in Western therapy without understanding its cultural context. An autoethnographic case study highlights that integrating micro- and macroperspectives can enhance therapeutic outcomes. While the metacognitive counselling approach may improve effectiveness for both clients and therapists, the need for broader data collection is essential; current insights stem from limited experiences. This raises awareness about the potential psychological impacts of ayahuasca and emphasizes careful, informed integration into Western psychotherapy practices.
Abstract
Abstract Ayahuasca is a hallucinogenic plant used throughout South America for religious, cultural and healing ceremonies. Previous studies have an...